Viewpoints

An Unusual Threat: Pharma is Already Tackling the Monkeypox Outbreak

June 02, 2022

Cases of monkeypox are rising around the world, but it is unlikely the virus will become a pandemic problem.

Law and Pharma

May 02, 2022

A long-running criminal case involving the theft of confidential data from a pharma giant is still unravelling, as more convictions are made.

A Future Investment

April 02, 2022

The AMR Action Fund has made its first investments, marking an important step forward for the partnership to achieve its goal of bringing new treatments to the market for priority pathogens.

Research Shows that Junk DNA Encodes Essential Immune and Metabolism Instructions

April 01, 2022

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

Why Global Pharma Companies Aren’t Quitting China Anytime Soon

March 08, 2022

What if we are underestimating China’s response to US/EU inshoring?

Standing in Solidarity

March 02, 2022

As Russia’s invasion of Ukraine continues, industry leaders speak out in condemnation of the actions taking place and pledge to provide aid to those in need.

The Price Debate

February 02, 2022

As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.

Celebrate the New

February 02, 2022

The process of reshaping inevitably leads to fresh insights.

Changes Afoot: 2022 Outlook for Pharma and its People

January 03, 2022

An obvious theme for 2021 has been COVID-19, but the next 12 months will see industry and its people experiencing further change.

Hot Picks for 2022

January 02, 2022

Overall, 2021 proved to be another good year for drug approvals in Europe, albeit with a slight disappointment for Alzheimer’s patients, but what should industry be watching out for in 2022?